 "Aurobindo pharma to acquire select products in France from Teva")
Aurobindo Pharma has inked a pact to acquire select commercial products in France from Teva for an undisclosed amount.
Arrow Generiques SAS, the French subsidiary of the company "will acquire the right, title and interest in products Calcium and Calcium Vitamin D3, including the use of the Orocal trademark from Teva", Aurobindo Pharma said in a BSE filing.
The two companies intend to ensure continuity of the supply of the products to the market, it added.
Following the receipt of clearances from European authorities, Arrow Generiques will integrate these products with its existing commercial operations in France, Aurobindo Pharma said.
"This acquisition will enable Arrow Generiques to continue to increase its branded products portfolio and leverage its position as a key player in the drug market," it added.
Shares of Aurobindo Pharma closed 4.07% up at Rs 739.90 on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%